This upregulation of BTG2 by compounds with vastly different mechanisms and p53 induction profiles emphasizes its importance in the cellular response to DNA damage and reveals its critical role in mediating the p53 response to chemotherapy used to treat CRC. This evidence concerns the gene TP53 and colorectal carcinoma.